

## **Supplementary Information**


### **Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma**

Hua-Dong Chen, Chen-Song Huang, Qiong-Cong Xu, Fuxi Li, Xi-Tai Huang, Je-Qin Wang, Shi-jin Li, Wei Zhao, and Xiao-Yu Yin

#### **Contents**

**Supplementary Figure 1**

**Supplementary Table 1-2**



**Figure S1. THZ1 inhibited ICC cell sphere formation and induced G2/M cell cycle arrest *in vitro* (related to Figure 4).**

A. Tumor sphere formation in RBE and SSP-25 cells upon treatment with different concentrations of THZ1 (100 nM or 150 nM) or 1% DMSO on day 5. The representative images were taken on day 7. Scale bar = 100  $\mu$ m.

B. Cell cycle analysis of RBE and SSP-25 cells upon THZ1 treatment (100 nM or 150 nM) with different concentrations for 48 h.



**Table S1. The clinicopathological characteristics of 96 ICC patients**

Characteristics	Values
Age, year (mean $\pm$ SD)	57.31 $\pm$ 11.6 (21-79)
Gender (male/female)	53/43
Tumor size, cm ( $\leq 5$ / $> 5$ )	37/59
CA19-9, kU/L ( $\leq 37$ / $> 37$ )	45/51
TNM stage (I/II/III/IV)	29/14/35/18
T stage (I/II/III/IV)	39/27/4/26
Lymphatic metastasis (Negative, Positive)	65/31
Distant metastasis (Negative, Positive)	16/80
TBIL, $\mu$ mol/L ( $\leq 37$ / $> 37$ )	78/18
Vascular invasion (Negative, Positive)	79/17
Nerve invasion (Negative, Positive)	83/13
Tumor recurrence, months (mean $\pm$ SD)	17.1 $\pm$ 22.8 (1-118)
Overall survival, months (mean $\pm$ SD)	21.7 $\pm$ 22.8 (1-118)

**Table S2. Sequences of primers and siRNA used for experiments in this study**

Names	Sequences
GAPDH-primer-F	AGATCATCAGCAATGCCTCCT
GAPDH-primer-R	TGAGTCCTTCCACGATACCAA
CDK7-primer-F	ATGGCTCTGGACGTGAAGTCT
CDK7-primer-R	GCGACAATTTGGTTGGTGTTTC
CDK7-siRNA-1-sense	GGACAUAGAUCAGAAGCUA
CDK7-siRNA-2-sense	GCUAAGUCAUCCAAAUAUA
AURKA-primer-F	TTGGGTGGTCAGTACATGCT
AURKA-primer-R	CCTGGCTCCCTCTGTTACAA
AURKB-primer-F	TTTGAGATTGGGCGTCCTCT
AURKB-primer-R	ATCACCTTCTTCCCATGGCA
CDC25B-primer-F	AAAGACCTTCCGCCTCAAGA
CDC25B-primer-R	ACCCACACCATCTTTCCCAT
CDK1-primer-F	GGGGTCAGCTCGTTACTCAA
CDK1-primer-R	TGACATGGGATGCTAGGCTT
CCNA2-primer-F	CACTCTACACAGTCACGGGA
CCNA2-primer-R	AGTGTCTCTGGTGGGTTGAG
MKI67-primer-F	AGCTCAAGATTCCAAGGCCT
MKI67-primer-R	CCAGAAATGGGATCAGCTGC

---

MET-primer-F	CCCACCCTTTG TTCAGTGTG
MET-primer-R	AGTCAAGGTGCAGCTCTCAT
AKT1-primer-F	GCCCAACACCTTCATCATCC
AKT1-primer-R	ACACCTCCATCTCTTCAGCC
PTK2-primer-F	AATCGGCCCCAGAAGAAGGAA
PTK2-primer-R	CGCAATGGTTAGGGATGGTG
CRK-primer-F	AAGTATAGACCTGCCTCCGC
CRK-primer-R	AACCTTTACCAGCTCACCGA
PDPK1-primer-F	TTTCAGGACGACGAGAAGCT
PDPK1-primer-R	TCCCTGTGAATGATGCCCTT
ARF6-primer-F	CTGTGGGTTTCAACGTGGAG
ARF6-primer-R	TTATGGCGTCCCTCATCTCC

---